 Zacks Investment Research upgraded shares of Concert Pharmaceuticals NASDAQ:CNCE from a hold rating to a buy rating in a research note issued to investors on Tuesday, Zacks.com reports. Zacks Investment Research currently has 11.00 price objective on the biotechnology companys stock. According to Zacks, Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on ... 